|
COLCHICINE INCREASES EFFECT OF THE DRUG BY REDUCING ITS METABOLISM
|
CO-ADMINISTRATION OF NSAIDS ELEVATE AND PROLONG SERUM METHOTREXATE CONCENTRATIONS RESULTING IN DEATHS FROM SEVERE HEMATOLOGIC AND GASTROINTESTINAL TOXICITY; CONCURRENT AND/OR SEQUENTIAL USE OF NSAIDS WITH HIGH DOSE METHOTREXATE SHOULD BE AVOIDED
|
MYCOPHENOLATE COMPETES WITH OTHER DRUGS WHICH UNDERGO ACTIVE RENAL TUBULAR SECRETION RESULTING IN INCREAED CONCENTRATION OF EITHER DRUGS.
|
|
VIT B12 ABSORPTION FROM THE GUT IS EFFECTED BY THE DRUG
|
VIT B12 ABSORPTION FROM THE GUT IS EFFECTED BY THE DRUG
|
SERUM LEVELS OF COLCHICINE MAY INCREASE ON CO-ADMINISTRATION
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|